Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis

Rituximab was first used as a treatment for B-cell malign lymphoma, and it is currently used in the treatment of rheumatoid arthritis. On the other hand, an association between rheumatoid arthritis with another autoimmune disease Hashimoto’s thyroiditis is a condition that can be expected. Thirty-four-year-old female patient with rheumatoid arthritis received disease-modifying agents in various combinations for 9 years. Due to unresponsiveness to treatment, the biological agent rituximab was initiated. The patient also had euthyroided Hashimoto’s thyroiditis and nodular goiter for 15 years. At the time of the diagnosis of Hashimoto thyroiditis, anti-thyroid peroxidase (anti-TPO): 45 IU/mL (0-35), anti-thyroglobulin (anti-Tg) >3000 IU/mL (0-115) but after 4 cycles of treatment with rituximab anti-TPO: 7.38 U/mL (0-35), anti-Tg